EP 682 Antiplatelet and Anticoagulant Management in Endoscopy

Clicks: 1
ID: 324085
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #426 of 432 articles by views in the british journal of surgery

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 432 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Antiplatelets and anticoagulants are commonly encountered in patients undergoing endoscopic procedures. While these increase bleeding risk, inappropriate interruption may increase thromboembolic risk. The British Society of Gastroenterology (BSG) published updated guidance in 2021 outlining recommendations for peri-endoscopic management of these medications. We aimed to assess local compliance with these guidelines. We conducted a retrospective cohort audit including all patients on antiplatelets and/or anticoagulants undergoing endoscopy at our unit in December 2025. Patients were identified from the endoscopy department list, and electronic patient records were reviewed. Variables include demographics, type and risk of endoscopic procedure, antithrombotic agent and indication, timing of medication interruption and documentation of post-procedure restarting instructions. A total of 124 patients were identified (66% male, median age 73 years). 58 patients were on aspirin, 31 on P2Y12 antagonists, 38 on DOACs and 3 on warfarin. Pre-procedure compliance was 100% for aspirin, 38.7% for P2Y12 antagonists, 21.2% for DOACs and 0% for warfarin, with unnecessary interruption in low-risk procedures. Post-procedure compliance was 8.6% for aspirin, 41.9% for P2Y12 antagonists, largely due to absent or incorrect restarting instructions. Compliance for warfarin was 100% and 63.2% for DOACs. This audit demonstrates variable compliance with the BSG guidelines, with frequent inappropriate interruption of antiplatelet and anticoagulant therapy in low-risk procedures and poor documentation of restarting instructions. We plan to raise awareness of these guidelines through summary posters, linking within local guidelines and presentation to the local unit. A re-audit is planned in 4months to assess the impact of these interventions.
Reference Key
openalex_W7172539836 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors S Yew, B S Kamera
Journal the british journal of surgery
Year 2026
DOI
10.1093/bjs/znag087.643
URL
https://doi.org/10.1093/bjs/znag087.643
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.